Get started
Author

Dylan M. Barth

Observed names: Barth, Dylan, Dylan Barth
ORCID: 0000-0002-9061-158X
Observed ORCID: 0000-0002-9061-158X
OpenAlex ID: A5066971190
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
2022 · Yazan Numan, Zaid Abdel Rahman, et al. · American Journal of Hematology · 46
PDF
Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis
2020 · Rachel J. Bubik, Dylan M. Barth, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 30
Linezolid and fentanyl: An underrecognized drug‐to‐drug interaction
2020 · Cristina Corsini Campioli, Dylan Barth, et al. · Journal of Clinical Pharmacy and Therapeutics · 9
PDF
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia
2023 · Lauren T. Shinn, Lydia L. Benitez, et al. · International Journal of Hematology · 5
Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience
2020 · Carlos Galvez, Imran Nizamuddin, et al. · Blood · 3
Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population
2022 · Dylan Barth, Michael Singleton, et al. · Cell Transplantation · 2
Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors
2020 · Yazan Numan, Zaid Abdel Rahman, et al. · Blood · 1
Use of Cystatin C to Assess Immunotherapy Toxicity in a Patient With Melanoma
2020 · Dylan M. Barth, Danielle Otto, et al. · Journal of Pharmacy Practice
Tumor growth model choice in the presence of limited data.
2015 · Carson Huey-You, Dylan Barth, et al. · Bulletin of the American Physical Society
Works count: 11
Citation count: 96
H-index: 4
I10-index: 2
Year
Topic
Type